The two parallel Antibody Mediated Prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition. Here we analyzed HIV-1 acquisition in AMP through the Week 104 final study visit. Against viruses considered...
A. deCamp, M. Juraska, Li Li et al.· Science Translational Medici...· 0 citations
The relationship between SARS-CoV-2-specific T cell responses and COVID-19 risk is incompletely understood, particularly after variant-adapted booster receipt. We assessed Spike-specific and Nucleocapsid-specific CD4+ and CD8+ T cell responses, measured by validated 27-color intracellular cytokine staining assay, as co...
Bo Zhang, You-Yi Fong, Chen-Chen Yu et al.· Nature Communications· 0 citations
Progress is being made in developing vaccine immunogens that induce bnAb B cell lineages in humans and the remaining tasks needed to complete a prototype HIV vaccine are outlined.
B. Haynes, Chen-Hao Yeh, L. Baden· Current Opinion in HIV and A...· 0 citations
BACKGROUND
Post-acute sequelae of SARS-CoV-2 infection, more commonly known as long COVID, has emerged as a major health problem. The pathogenesis of long COVID is unknown, but among the leading hypotheses is viral persistence. We aimed to investigate whether the use of the SARS-CoV-2 antiviral nirmatrelvir-ritonavir i...
L. Baden, N. Shah, Sean T. H. Liu et al.· Lancet. Infectious Diseases...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.